Headlines about Amdocs (NASDAQ:DOX) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amdocs earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 46.3100162713939 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Amdocs from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Friday, November 10th. BidaskClub downgraded shares of Amdocs from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 16th. Jefferies Group restated a “hold” rating and issued a $70.00 price target on shares of Amdocs in a research report on Thursday, October 12th. Robert W. Baird restated a “hold” rating and issued a $66.00 price target on shares of Amdocs in a research report on Friday, October 20th. Finally, Oppenheimer restated a “buy” rating and issued a $77.00 price target on shares of Amdocs in a research report on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. Amdocs has a consensus rating of “Hold” and a consensus price target of $70.29.
Shares of Amdocs (DOX) traded up $0.60 during trading hours on Friday, hitting $67.59. 516,542 shares of the company traded hands, compared to its average volume of 536,881. The stock has a market cap of $9,640.82, a P/E ratio of 22.83, a PEG ratio of 2.30 and a beta of 0.52. Amdocs has a fifty-two week low of $56.10 and a fifty-two week high of $67.98.
Amdocs (NASDAQ:DOX) last released its earnings results on Wednesday, November 8th. The technology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.05. Amdocs had a net margin of 11.30% and a return on equity of 14.77%. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $977.72 million. During the same quarter in the prior year, the firm earned $0.89 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. research analysts predict that Amdocs will post 3.72 EPS for the current fiscal year.
Amdocs announced that its board has initiated a share repurchase program on Wednesday, November 8th that authorizes the company to repurchase $800.00 million in shares. This repurchase authorization authorizes the technology company to buy shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 19th. Shareholders of record on Friday, December 29th will be given a $0.22 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.88 dividend on an annualized basis and a yield of 1.30%. Amdocs’s payout ratio is 29.73%.
Amdocs Company Profile
Amdocs Limited is a provider of software and services for communications, entertainment and media industry service providers. The Company develops, implements and manages software and services associated with business support systems (BSS), operational support systems (OSS) and network operations to enable service providers to introduce new products and services, process orders, monetize data, support new business models and enhance their understanding of their customers.
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.